Hims & Hers, a prominent online provider of obesity medications, announced on March 15, 2024, that it will cease the sale of a knockoff version of Novo Nordisk’s weight-loss pill, Wegovy. This decision follows regulatory scrutiny suggesting that the product may not comply with federal laws governing medication sales.
The company had only introduced the alternative pill on March 14, 2024, but faced immediate backlash. The top lawyer for the Department of Health and Human Services, Mike Stuart, publicly criticized the offering. On March 15, he indicated on social media that his office had referred Hims to the Justice Department for potential legal violations concerning medication distribution.
In a statement, Hims & Hers acknowledged that the decision to withdraw the product was made after “constructive conversations with stakeholders across the industry.” The company had aimed to tap into the increasing consumer interest in Wegovy, which has gained significant traction since its launch in early January 2023. Approximately 170,000 people have purchased the Wegovy pill, which is priced at $149 for the first month and $199 for subsequent months.
The original Wegovy pill, which is now available in tablet form, has been highlighted on TrumpRx, a government website designed to assist patients in finding lower prices for specific medications. Interestingly, Hims & Hers launched its version just hours before President Trump unveiled the TrumpRx site. Their offering, priced at $49 for the initial month and $99 thereafter, was positioned as a cheaper alternative to Novo’s product.
However, the competitive pricing strategy quickly drew the attention of federal regulators. The swift response from the Department of Health and Human Services reflects the increasing scrutiny on the pharmaceutical industry, particularly regarding pricing and compliance with health regulations.
The withdrawal of the pill by Hims & Hers underscores the challenges faced by companies trying to navigate the complex landscape of medication sales and regulatory compliance. As the demand for weight-loss medications continues to grow, the focus on legality and safety remains paramount for both consumers and providers in this sector.
As the market for obesity treatments evolves, it is expected that companies will need to prioritize compliance and transparency to avoid similar issues in the future.
